DE69629837D1 - (-)cis-6(s)-phenil-5(r)(4-(2-pyrrolidin-1-yl ethoxy)phenyl)-5,,6,7,8-tetrahydronaphtalen-2-ol-d-tartrate - Google Patents

(-)cis-6(s)-phenil-5(r)(4-(2-pyrrolidin-1-yl ethoxy)phenyl)-5,,6,7,8-tetrahydronaphtalen-2-ol-d-tartrate

Info

Publication number
DE69629837D1
DE69629837D1 DE69629837T DE69629837T DE69629837D1 DE 69629837 D1 DE69629837 D1 DE 69629837D1 DE 69629837 T DE69629837 T DE 69629837T DE 69629837 T DE69629837 T DE 69629837T DE 69629837 D1 DE69629837 D1 DE 69629837D1
Authority
DE
Germany
Prior art keywords
tetrahydronaphtalen
phenil
pyrrolidin
tartrate
cis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69629837T
Other languages
English (en)
Other versions
DE69629837T2 (de
Inventor
K Chiu
Morgan Meltz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of DE69629837D1 publication Critical patent/DE69629837D1/de
Publication of DE69629837T2 publication Critical patent/DE69629837T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69629837T 1995-11-02 1996-10-04 (-)cis-6(s)-phenil-5(r)(4-(2-pyrrolidin-1-yl ethoxy)phenyl)-5,,6,7,8-tetrahydronaphtalen-2-ol-d-tartrate Expired - Lifetime DE69629837T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US612595P 1995-11-02 1995-11-02
US6125P 1995-11-02
PCT/IB1996/001049 WO1997016434A1 (en) 1995-11-02 1996-10-04 (-) cis-6(s)-phenyl-5(r)[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol d-tartrate

Publications (2)

Publication Number Publication Date
DE69629837D1 true DE69629837D1 (de) 2003-10-09
DE69629837T2 DE69629837T2 (de) 2004-05-06

Family

ID=21719433

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69629837T Expired - Lifetime DE69629837T2 (de) 1995-11-02 1996-10-04 (-)cis-6(s)-phenil-5(r)(4-(2-pyrrolidin-1-yl ethoxy)phenyl)-5,,6,7,8-tetrahydronaphtalen-2-ol-d-tartrate

Country Status (43)

Country Link
US (1) US5948809A (de)
EP (1) EP0876359B1 (de)
JP (1) JP3088020B2 (de)
KR (1) KR19990067280A (de)
CN (1) CN1067065C (de)
AP (1) AP713A (de)
AR (1) AR004078A1 (de)
AT (1) ATE248827T1 (de)
AU (1) AU708841B2 (de)
BG (1) BG63943B1 (de)
BR (1) BR9611436A (de)
CA (1) CA2236673C (de)
CO (1) CO4770967A1 (de)
CZ (1) CZ287341B6 (de)
DE (1) DE69629837T2 (de)
DK (1) DK0876359T3 (de)
DZ (1) DZ2114A1 (de)
EG (1) EG21095A (de)
ES (1) ES2203713T3 (de)
GT (1) GT199600085A (de)
HR (1) HRP960503B1 (de)
HU (1) HU227521B1 (de)
IL (1) IL124027A (de)
IS (1) IS1855B (de)
MA (1) MA23998A1 (de)
NO (1) NO310358B1 (de)
NZ (1) NZ318498A (de)
OA (1) OA11009A (de)
PE (1) PE17698A1 (de)
PL (1) PL188633B1 (de)
PT (1) PT876359E (de)
RO (1) RO119829B1 (de)
RU (1) RU2162465C2 (de)
SI (1) SI0876359T1 (de)
SK (1) SK282172B6 (de)
TN (1) TNSN96134A1 (de)
TR (1) TR199800783T2 (de)
TW (2) TW518327B (de)
UA (1) UA51676C2 (de)
UY (1) UY24362A1 (de)
WO (1) WO1997016434A1 (de)
YU (1) YU49123B (de)
ZA (1) ZA969212B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB9703109D0 (en) * 1997-02-14 1997-04-02 Smith & Nephew Compositions
EP0966968B1 (de) 1998-06-16 2004-05-06 Pfizer Products Inc. Kombinationstherapeutika, enthaltend einen selektiven Östrogenrezeptormodulator und Prostaglandin E2
ZA993975B (en) * 1998-06-16 2000-12-15 Pfizer Prod Inc Combination therapy for musculoskeletal frailty.
BR9911357A (pt) * 1998-06-16 2001-03-13 Pfizer Producs Inc Combinações terapêuticas de moduladores (seletivos) de receptor de estrogênio (serm) e secretagogos de hormÈnio de crescimento (ghs) para tratar fragilidade músculo-esqueletal
YU26700A (sh) * 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
CO5271696A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
ATE333450T1 (de) 2000-04-07 2006-08-15 Pfizer Prod Inc Metabolite von estrogen-agonisten/-antagonisten
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
EP1156120B1 (de) 2000-05-08 2006-11-22 Pfizer Products Inc. Enzymatische Spaltung von selektiven Modulatoren des Östrogenrezeptors
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
KR100568380B1 (ko) * 2001-05-01 2006-04-05 화이자 프로덕츠 인코포레이티드 저 투약량 약학 조성물의 제조 방법
HUP0401268A2 (hu) 2001-07-31 2004-11-29 Pfizer Products Inc. Ösztrogén agonisták/antagonisták, ösztrogének és progesztinek kombinációját tartalmazó gyógyszerkészítmények, valamint eljárás ezek előállítására
RU2317104C2 (ru) * 2001-09-24 2008-02-20 Импиэриэл Инноувейшнс Лимитид Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
WO2003082814A1 (en) * 2002-03-28 2003-10-09 Pfizer Products Inc. Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US7444197B2 (en) 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
MXPA06015170A (es) * 2004-06-21 2007-08-21 Pharmacia & Upjohn Co Llc Procedimiento para aumentar la cantidad de hueso.
US20070249623A1 (en) * 2004-06-30 2007-10-25 Eli Lilly And Company Patent Division 1-(Indole-6-Carbonyl-D-Phenylglycinyl)-4-(1-Methylpiperidin-4-Yl)Piperazine D-Tartrate
DE602006017217D1 (de) 2005-06-22 2010-11-11 Pfizer Prod Inc Stereoselektives hydrierverfahren zur herstellung von cis-6-phenyl-5-ä4-(2-pyrrolidin-1-yl-ethoxy)-phenylü-2-methoxy-5,6,7,8-tetrahydronaphthalin-hydrochlorid
CZ2007373A3 (cs) * 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
US8937188B2 (en) 2009-04-29 2015-01-20 Glenmark Generics Ltd. Process for the preparation of lasofoxifene tartrate
KR101149529B1 (ko) 2009-09-11 2012-05-25 한국화학연구원 인덴온 유도체 및 이를 포함하는 약학적 조성물
CN103113323B (zh) * 2013-02-05 2015-11-11 南京华威医药科技开发有限公司 酒石酸拉索昔芬中间体的制备方法
CN112353796A (zh) 2016-10-11 2021-02-12 杜克大学 Er+乳腺癌的拉索昔芬治疗
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
KR20220115062A (ko) 2021-02-09 2022-08-17 (주)오스티오뉴로젠 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3234090A (en) * 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
US3522319A (en) * 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

Also Published As

Publication number Publication date
HUP9900087A3 (en) 1999-11-29
CA2236673C (en) 2002-03-19
GT199600085A (es) 1998-04-04
TR199800783T2 (xx) 1998-08-21
KR19990067280A (ko) 1999-08-16
PL188633B1 (pl) 2005-03-31
TW581766B (en) 2004-04-01
EP0876359B1 (de) 2003-09-03
US5948809A (en) 1999-09-07
OA11009A (en) 2003-03-03
AP713A (en) 1998-12-28
HRP960503A2 (en) 1998-04-30
DZ2114A1 (fr) 2002-07-22
EG21095A (en) 2000-10-31
DE69629837T2 (de) 2004-05-06
CN1067065C (zh) 2001-06-13
IL124027A (en) 2001-10-31
NO310358B1 (no) 2001-06-25
TNSN96134A1 (fr) 1998-12-31
WO1997016434A1 (en) 1997-05-09
UY24362A1 (es) 1997-04-24
JP3088020B2 (ja) 2000-09-18
AU708841B2 (en) 1999-08-12
CZ132098A3 (cs) 1999-03-17
BR9611436A (pt) 1999-03-23
IS4718A (is) 1998-04-16
AR004078A1 (es) 1998-09-30
AU6998496A (en) 1997-05-22
YU57896A (sh) 1998-12-23
NZ318498A (en) 1999-06-29
TW518327B (en) 2003-01-21
NO981962L (no) 1998-04-30
JPH11502866A (ja) 1999-03-09
AP9600880A0 (en) 1997-01-31
HUP9900087A2 (hu) 1999-05-28
MX9803544A (es) 1998-09-30
RU2162465C2 (ru) 2001-01-27
IS1855B (is) 2003-02-21
BG102474A (en) 1999-06-30
ZA969212B (en) 1998-05-04
HRP960503B1 (en) 2001-12-31
HU227521B1 (en) 2011-07-28
RO119829B1 (ro) 2005-04-29
BG63943B1 (bg) 2003-07-31
CN1201458A (zh) 1998-12-09
EP0876359A1 (de) 1998-11-11
SK282172B6 (sk) 2001-11-06
UA51676C2 (uk) 2002-12-16
CO4770967A1 (es) 1999-04-30
NO981962D0 (no) 1998-04-30
CZ287341B6 (en) 2000-10-11
MA23998A1 (fr) 1997-07-01
ATE248827T1 (de) 2003-09-15
PL326498A1 (en) 1998-09-28
SI0876359T1 (en) 2003-12-31
CA2236673A1 (en) 1997-05-09
ES2203713T3 (es) 2004-04-16
YU49123B (sh) 2004-03-12
PE17698A1 (es) 1998-04-18
SK54298A3 (en) 1999-07-12
PT876359E (pt) 2003-12-31
DK0876359T3 (da) 2003-11-24

Similar Documents

Publication Publication Date Title
DE69629837D1 (de) (-)cis-6(s)-phenil-5(r)(4-(2-pyrrolidin-1-yl ethoxy)phenyl)-5,,6,7,8-tetrahydronaphtalen-2-ol-d-tartrate
DK0828488T3 (da) Isothiazoloner
PT846422E (pt) Formula infantil anti-regurgitacao
FI974172A0 (fi) B-adrenergisiä agonisteja
PT853617E (pt) Novos derivados de 2,3-dioxo-1,2,3,4-tetrahidro-quinoxalinilo
DE69612262T2 (de) Riemenscheibe
DK0820451T3 (da) Hidtil ukendte heterocykliske forbindelser
DE69612151D1 (de) Riemenscheibe
FI950512A0 (fi) Ny konserveringssammansaettning
FI974170A0 (fi) B-adrenergisiä agonisteja
EE9600011A (et) Uudsed dialkoksü-püridinüül-bensimidasooli derivaadid
NO961404D0 (no) 4-indolylpiperazinyl-derivater
DE69712744D1 (de) 2,2-dibromo-3-nitrilopropionamid suspensionsformulierungen
MA26481A1 (fr) Derives d'arylsecocholadiene
KR960038766U (ko) 마킹 겸용 트레이
DK0851865T3 (da) Hidtil ukendte heterocykliske forbindelser
FI950298A0 (fi) Central-DC-laogspaenningskaella
ITTE950004V0 (it) Basamento smontabile
KR960034494U (ko) 종이 컵 회수기
DK0941082T3 (da) Hidtil ukendt anvendelse for 1,3-propandiolderivater
KR970011998U (ko) 이동식 옷걸이
KR960031961U (ko) 풀리
KR970043195U (ko) 풀리
ITMO950113A0 (it) Puleggia
KR960030239U (ko) 소반

Legal Events

Date Code Title Description
8364 No opposition during term of opposition